GlaxoSmithKline, the original branded maker of branded Zantac, halted global distribution of its heartburn medicine, according to Bloomberg.
The move comes after health regulators in the U.S. and Europe flagged a potential human carcinogen in the drug.
GlaxoSmithKline will recall the drug in India, where the drug is called Zinetac, and Hong Kong. The recalled medicine is made with an active ingredient from India.
GlaxoSmithKline first won FDA approval for Zantac in 1983, though it later discontinued it as more generic makers entered the market. Currently, about two dozen drugmakers sell a generic version of Zantac.
GlaxoSmithKline doesn't market its version of the drug in the U.S.or Canada but does sell it in some Euopean countries.
A recall means drugs must be pulled from the shelves, while a halt on distribution means the company will no longer supply the drugs.
Read the full report here.